Dermatology and Therapy
@DermatolTher
PubMed-indexed, rapid publication, peer reviewed #openaccess journal. Impact Factor 3.4. CiteScore 4.9. Part of @AdisJournals
ID:887628275828355072
http://www.springer.com/springer+healthcare/journal/13555 19-07-2017 11:00:47
874 Tweets
2,0K Followers
2,1K Following
Follow People
The aim of our latest published review was to investigate the effectiveness and safety of biologic drugs acting on molecular mechanisms involved in the pathogenesis of #psoriasis in preventing #cardiovascular complications: link.springer.com/article/10.100…
This newly published study evaluated the effect of #tildrakizumab treatment on work productivity and activity impairment during 64 weeks of treatment: link.springer.com/article/10.100… #Psoriasis #OpenAccess
The objective of this study was to measure the effect of introducing the frequent use of #makeup on improving #depressive symptoms in adult women of medium–low purchasing power: link.springer.com/article/10.100… #Beauty #MentalHealth
This study evaluated the association of adjuvant radiation therapy (ART) with clinical risk factors in ART-treated and untreated patients and showed the clinical utility of the 40-gene expression profile (40-GEP) for guiding ART: link.springer.com/article/10.100… #SquamousCellCarcinoma
In this study, authors aim to better characterize the environmental impact of in-person conferences as well as describe the reduction in carbon emissions associated with virtual conference attendance:: link.springer.com/article/10.100… #Emissions #Conference #VirtualLearning #CarbonDioxide
This exploratory analysis evaluated the maintenance of response per Investigator’s Static Global Assessment (ISGA; ISGA score of 0 [clear] or 1 [almost clear]) during the CrisADe CONTROL trial through week 52: link.springer.com/article/10.100… #Crisaborole #AtopicDermatitis #Flare
This post hoc analysis compared the achievement of #NationalPsoriasisFoundation target and acceptable responses for #ixekizumab versus other biologics: link.springer.com/article/10.100… #Psoriasis
This study aimed to understand treatment response dynamics, including factors associated with favorable response, among patients with moderate-to-severe psoriasis who received #guselkumab , #adalimumab , or #secukinumab : bitly.ws/3fYmN #psoriasis #treatment
Development and Psychometric Validation of a Patient-Reported Outcome Measure to Assess the Signs and Symptoms of #ChronicHandEczema : The Hand Eczema Symptom Diary (HESD): bitly.ws/3fYm4 #DELTA1trial #Phase3 #Itch #Delgocitinib
#Secukinumab is an anti-interleukin (IL)-17A monoclonal antibody indicated for multiple immunological disorders. Here, authors aim to summarize secukinumab safety in #ClinicalTrials and post-marketing setting until 25 June 2022: link.springer.com/article/10.100…
The objective of this real-world analysis was to describe disease control and #physician satisfaction among #patients with mild to moderate #AtopicDermatits who have been prescribed #ruxolitinib cream: link.springer.com/article/10.100…
The aim of the current study was to assess the real-world effectiveness and tolerability of an ADE-G2-containing cream for the management of #WoundHealing and minor #dermatologic conditions that impact the #skin barrier: link.springer.com/article/10.100…
Here, authors describe the clinical and demographic characteristics, treatments received, and negative health outcomes experienced among patients with #PalmoplantarPustulosis in the United States and Germany. Read this article in full here: bitly.ws/3f7Ve
To consolidate the literature on the burden of recurrent #HerpesZoster , authors conducted a non-systematic literature review, and discuss what is known about the incidence of, risk factors for, and clinical features of recurrent herpes zoster: link.springer.com/article/10.100…
This study evaluated the stratification of risk by the 40-GEP test in a large cohort of tumors with one or more high-risk factors and in clinically relevant subgroups: Read this article in full here: link.springer.com/article/10.100… #CutaneousSquamousCellCarcinoma
#SkinCancer #Prognosis
This multicenter, randomized, double-blind, placebo-controlled, repeat-dose study assessed the efficacy, safety, pharmacokinetics, and pharmacodynamics of 960 mg #GSK2982772 in patients with moderate to severe plaque #psoriasis : bitly.ws/3ejdy
The purpose of this newly published study was for a panel of experts in #psoriasis management to synthesize current literature and provide consensus statements with guidance on use of #bimekizumab . Read in full here: link.springer.com/article/10.100…